IL-2 transmembrane construct
AssigneeUniversity of Utah Research Foundation
InventorsWolfram Samlowski, Nathan Bradley Adams, John McGregor
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Utah Research Foundation
InventorsWolfram Samlowski, Nathan Bradley Adams, John McGregor
Estimating the term…
Compounds, genetic constructs, and cancer treatment methods are provided. Expression vectors were designed to express fusion genes including hIL-2 with a Fcε-γ transmembrane anchor derived from a subunit of the FC epsilon receptor. mRNA and the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by microscopy. RD995 cells transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into C3H/HEN mice. Tumors of mice implanted with 106 or 105 RD995 cells transfected with IL-2tm grew slower than controls. It is believed that selective expression of cytokines such as IL-2 on the surface of tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition and killing, potentially avoiding toxicity associated with known cytokine therapies.
A nucleic acid molecule encoding a fusion protein comprising;
A method of producing a polypeptide comprising the amino acid sequence of the polypeptide in a cell comprising;
Dependencies are inferred from the claim text.